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Abstract: Two consecutive multi-center phase II trials were designed to prove the hypothesis, whether therapeutic model-
ing of tumor-associated inﬂ  ammatory processes could result in improved tumor response.
Therapy in both trials consisted of low-dose capecitabine 1g/m2 twice daily p.o. for 14 days, every 3 weeks, day 1+, and 
rofecoxib 25 mg daily p.o., day 1+ (from 11/04 etoricoxib 60 mg daily instead) plus pioglitazone 60 mg daily p.o., day 1+. 
In study II low-dose IFN-α 4.5 MU sc. three times a week, week 1+, was added until disease progression.
Eighteen, and 33 patients, respectively, with clear cell renal carcinoma and progressive disease were enrolled. Objective 
response (48%) was exclusively observed in study II (PR 35%, CR 13%), and paralleled by a strong CRP response after 4 
weeks on treatment, p = 0.0005, in all 29 pts (100%) with elevated CRP levels. Median progression-free survival could be 
more than doubled from a median of 4.7 months (95% CI, 1.0 to 10.4) to 11.5 months (6.8 to 16.2) in study II, p = 0.00001. 
Median overall survival of population II was 26 months. 
Efﬁ  cacious negative regulation of tumor-associated inﬂ  ammation by transcription modulators may result in a steep increase 
of tumor response and survival.
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Introduction
Increased C-reactive protein (CRP) levels in serum may be frequently observed in patients with meta-
static clear cell renal carcinoma (CCRC) [Ljungberg et al. 1997]. CRP as acute phase protein indicates 
the hepatocytes’ response to a systemic inﬂ  ammatory activity mediated by pro-inﬂ  ammatory cytokines 
(IL-6, IL-1, TNF-α) [Yoshida et al. 2002]. Particularly in CCRC, CRP may be additionally derived 
from the tumor cells itself [Jabs et al. 2005]. The presence of acute phase response as a negative predictor 
for survival is obvious [Bromwich et al. 2004; Kerr, 2006; Thiounn et al. 1997].
Hypoxia is an omnipresent phenomenon in growing tumors [Yan et al. 1995]. Particularly in CCRC 
the ‘hypoxic phenotype’ is based on mutations or gene silencing of the ‘Von-Hippel-Lindau’ tumor-
suppressor gene [Herman et al. 1994; Latif et al. 1993]. Genes induced by the consecutive accumulation 
of the transcription factor hypoxia-inducible factor alpha (HIF-α) include the vascular endothelial 
growth factor (VEGF), the platelet-derived growth factor, and NF-kappaB among others, providing 
targets for an combined angiostatic and anti-inﬂ  ammatory therapy in CCRC [Cummins and Taylor, 
2005;  An and Rettig, 2005]. Therefore, CCRC possesses model character for pharmacological inter-
ventions aimed to attenuate inﬂ  ammation and neoangiogenesis, e.g., with COX-2 inhibitors, glitazones, 
and IFN-α [Panigrahy et al. 2005; Prasad, 2006; Tilg et al. 1995].
Therapy of metastatic renal cell carcinoma (RCC) has to face a vexing problem: The resistance against 
currently available therapeutic approaches. Continuous production and release of pro-inﬂ  ammatory 
cytokines in metastatic CCRC, particularly IL-6, by tumor and adjacent stroma cells may account in part 
for the drug resistance [Galban et al. 2003; Angelo et al. 2002; Hodge et al. 2005]. Little is known of 
how pro-inﬂ  ammatory cytokines such as IL-6 serve to promote growth of metastatic tumors. Serum 
IL-6 levels, however, are well correlated to metastatic stage and ECOG status [Mantovani et al. 2002].
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Recently published data on the combined 
activity of pioglitazone and COX-2 inhibitors in 
metastatic cancer approved that cancer encom-
passes other diseases, such as inflammation:
Similarly to non-malignant typically inﬂ  amma-
tion-linked diseases, pioglitazone (peroxisome 
proliferator-activated receptor-gamma, PPAR-γ 
agonist) may induce response in malignant 
diseases such as e.g., vascular sarcomas while 
attenuating the host’s inﬂ  ammatory reaction to 
metastatic disease [Vogt et al. 2003; Reichle et 
al. 2004]. Moreover, results of a randomized 
phase II trial in metastatic melanoma are demon-
strating that the survival rate may be signiﬁ  cantly 
enhanced by the addition of anti-inﬂ  ammatory 
therapy (pioglitazone plus COX-2 inhibitor) to 
low-dose continuous (metronomic) chemotherapy 
[Reichle et al. 2005].
The two consecutive phase II trials are based 
on our recent experiences on anti-inﬂ  ammatory 
and angiostatic therapy in quite different metastatic 
malignancies [Hafner et al. 2005] and are aimed 
to study whether attenuation of tumor-related 
inﬂ  ammation by pioglitazone plus/minus IFN-α 
may result in an improved response rate in CCRC 
[Pascual et al. 2005; Tilg et al. 1995]. The biomod-
ulatory therapy in both trials is supplemented by 
low-dose chemotherapy (supposed angiostatic 
activity) with capecitabine [Oevermann et al. 
2000].
Patients and Methods
Participating centers in the trial were the Depart-
ment of Hematology and Oncology and the Depart-
ment of Urology of the University Hospital of 
Regensburg, Departments of Hematology and 
Oncology of the Hospitals Fürth and Passau. 
Eligibility
The local ethics committee approved the study 
protocol and patients were required to provide 
written informed consent before enrolment. 
Eligible patients were required to have progressive 
metastatic (according to RECIST requirements), 
locally recurrent or contra-lateral unresectable 
CCRC. If nephrectomy was not indicated due to 
missing operability clear cell histology was 
conﬁ  rmed at a metastatic site. Patients with primarily 
metastatic disease experienced nephrectomy at least 
21 days before the initiation of protocol treatment. 
In these patients disease progression was no
prerequisite for the start of therapy. Brain metas-
tases were no exclusion criteria, if those were 
controlled by surgery or radiotherapy prior to the 
start of study medication.
Patients were allowed to have received an 
unlimited number of previous systemic therapies 
including chemotherapy and/or immunotherapy or 
antiangiogenic agents such as thalidomide and 
IFN-α ( IFN-α pretreatment was no exclusion 
criterion, because we suggested a synergistic anti-
inflammatory activity of pioglitazone/COX-2 
inhibitor/IFN-α). Previous treatment with piogli-
tazone or capecitabine was an exclusion criterion. 
The remaining inclusion criteria included those of 
the Eastern Cooperation Oncology Group (ECOG) 
(with the exception of serum creatinine < 1.5 
mg/dL).
Pre-treatment evaluation
Aside from the acquisition of a medical history, 
baseline evaluation included a physical examina-
tion, an assessment of ECOG performance status, 
a complete blood cell count, serum chemistry 
assays, coagulation tests, a chest X-ray, abdominal 
ultrasound scanning, computed tomography (CT) 
(scanning of the thorax and abdomen, and faculta-
tive bone scanning or CT scanning of the brain if 
metastasis were clinically suspected).
Patients subsequently were monitored before 
the start of chemotherapy and every 3 weeks there-
after (assessment of toxicity, serum chemistry 
assays, one of which measured CRP levels, and a 
physical examination). For patients continuing 
study medication target lesions were assessed (via 
abdominal ultrasound or chest X-ray) before each 
3-week therapy cycle. If these techniques suggested 
response to treatment or progressive disease, CT 
scans were performed before the routinely sched-
uled response evaluations with CT scans in 12-
week intervals. 
Treatment
Patients in study I received 1 g/m
2 oral capecitabine 
(Roche) administered twice daily from day 1+, 60 
mg oral pioglitazone (Takeda) and 25 mg oral 
rofecoxib (MSD) daily starting with day 1+. From 
November 2004 we substituted rofecoxib for
60 mg oral etoricoxib (MSD) daily (rofecoxib was 
withdrawn from the market). Patients in study II 
received medication of study I plus 4.5 MU IFN-α sc. 
(Roche) 3 times per week, from day 1+.
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Treatment was continued until disease progres-
sion was documented or for a maximum of 6 weeks 
after conﬁ  rmation of complete remission.
Efﬁ  cacy assessment
Response was evaluated in patients who had a 
follow-up duration of ≥ 3 weeks by the treating 
physicians, and centrally (blinded) by the imaging 
unit of the university hospital of Regensburg. 
Response categories were assigned by using the 
Response Evaluation Criteria in Solid Tumors 
(RECIST) criteria [Gehan and Tefft, 2000]. All 
major responses were reconﬁ  rmed in 4- to 6-week 
intervals. Data reported represent the best response 
obtained during treatment according to study 
protocol.
Dose modiﬁ  cation
Drug administration was interrupted for respective 
grade 2 or 3 toxicity and resumed at a reduced dose 
on resolution to less than grade 2. In cases of reoc-
currence of dose-limiting grade 3 or 4 toxicity the 
corresponding drug was discontinued.
Capecitabine therapy was continued with 75% 
starting dose for the ﬁ  rst, and 50% for the second 
occurrence. IFN-α administration was continued 
at a dose of 3 MU three times a week; COX-2 
inhibitor administration at a dose of 12.5 mg rofe-
coxib or 60 mg etoricoxib every second day; and 
pioglitazone at a reduced dose of 45 mg. 
According to experiences in previous phase II 
studies dose modiﬁ  cation of pioglitazone was not 
performed as long as a dose reduction or discon-
tinuation of the COX-2 inhibitor was sufficient
to resolve edema and/or renal insufficiency
to < grade 2.
Statistical considerations
The current non-randomized phase II trials were 
designed to assess [1] response, [2] the qualitative 
and quantitative toxicity of the treatment schedules 
and [3] CRP response. 
The case calculation for each study based upon 
available response data following treatment with 
single agents or combinations of drugs adminis-
tered. We assumed a response rate > 25% to 
proceed with the further development of the respec-
tive schedule [Creagan et al. 1991; Zaniboni et al. 
1989; Haarstad et al. 1994]. Prerequisite to resume 
schedule II was a CRP decline > 30% in patients 
experiencing stable disease or objective response 
on schedule I independently of whether stage two 
of a two stage ﬂ  exible design may be achieved with 
schedule I [Chen and Ng, 1998]. 
With the assumption of an undesired response 
rate of 5% the rejection boundary is then one 
response, if the sample size is 17 patients. If the 
observed responses are > 1, we have to enroll 28 
patients at the second stage. Achievement of 7 
responses among 28 patients indicate a true 
response rate > 25%. The level of this design is 
5% and the power 0.9.
Progression-free survival was deﬁ  ned as the 
interval between the beginning of treatment and 
disease progression. Overall survival was calcu-
lated from the initiation of treatment until death or 
until November 2005 (date of ﬁ  nal data analysis), 
which ever came ﬁ  rst. Survival distribution was 
generated using Kaplan-Meier method. Survival 
analyses were performed on the intent-to treat 
population. Patients who withdrew from the study 
due to treatment related side effects were consid-
ered as treatment failure.
Comparison of survival for subsets of patients 
was accomplished by using two-sided log-rank 
analysis. In addition, the ‘Fischer’ exact and the 
‘Student t’ – test were used to identify signiﬁ  cant 
association between chemical and biologic 
variables.
Results
Patients characteristics
In total, 18 patients (of 2 centers) and 33 patients 
(of 4 centers) with unresectable CCRC were 
enrolled onto the study protocols between February 
2002 and January 2003 (study I) and February 2003 
and April 2005 (study II), respectively. Detailed 
patient characteristics are listed in Table 1. The age 
distribution in both cohorts corresponds to the age-
related incidence of renal cell carcinoma, and a 
typical metastatic pattern was documented. Only 
a small proportion of patients did not undergo 
radical nephrectomy (11%/ 9%, study I/II). Twelve 
and 23 patients in cohort I/II (67%/70%) received 
either previous surgery of metastases (17%/52%), 
and/or systemic treatment (33%/19%), and/or 
radiotherapy (17%/18%).
Retrospectively the patients were categorized 
according to the clinically guided Motzer score 
and to the Leibovich score which is adapted to 
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Table 1. Patient characteristics Study I and Study II.
      STUDY I                                STUDY II
      n = 18                                      n = 33
Characteristics  No. %  No. %
Age, years       
        Median              66               64
        Range              (53 – 85)               (48 - 78)
Sex      
        Male  13  72  21  64
        Female  5  28  12  36
ECOG  performance  status      
        0  3  17  7  21
        1  12  67  20  61
        2  3  17  6  18
Previous  nephrectomy  16 89  30 91
Previous surgery of metastasis  3  17  17  52
Site of metastasis         
        lung  9  50  27  82
        liver  3  17  7  21
        bone  4  22  12  36
        adrenal  1  5  1  3
        lymph nodes  4  22  12  36
        contralateral kidney  3  17  5  15
        ovary  1  5  -  -
        pancreas  -  -  4  12
        intestine  -  -  2  6
        skin  -  -  2  6
        thyreoid  -  -  1  3
Histologic grade       
        0-3  14  77  26  79
        4  1  6  3  9
        unspeciﬁ   ed  3 17  4 12
Motzer risk score       
        low (0)  4  22  8  24
        intermediate (1-2)  9  50  14  43
        high (3-5)  5  28  11  33
Leibovich score       
        Median              4.1                4.9
        Range                (- 1 to 9)                (- 1 to 9)
Previous systemic treatment       
        None  11  61  26  79
        Interferon  3  17  1  3
        Interferonα/  Interleukin-  2  1 5  1 3
        Velbe / IFNα/ IL-2  2  11  3  9
        5 Fluorouracil / IFNα/  IL-2  1 5  2 6
Previous  radiotherapy  3 17  6 18
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stage, metastatic site and histological qualities 
[Motzer, 2003; Leibovich et al. 2005]. The two 
cohorts differed neither in the Motzer nor in the 
Leibovich categories signiﬁ  cantly (Table 1). 
Treatment
All patients in study I/II received at least three
3-week cycles of study medication. Two patients 
of protocol II (6%) were withdrawn from response 
analysis because these patients received up-front 
alternative treatments, one on of her own decision 
another met one of the exclusion criteria (coumarin 
therapy). 
The median duration of treatment in study II 
was 11.5 months (95% CI, 7.3–15.7 months). At 
present, 16 patients (52%) are still on treatment for 
8.5+ to 23.5+ months including 4 patients with 
stable disease for 8.5–21.2 months. An additional 
two patients with continuous CR (protocol II) are 
still without study medication for 4.1+ and 7.3+ 
months. In study I, the median duration of
treatment was 4.7 months (95% CI, 0.9–10.4 
months). 
Treatment efﬁ  cacy
All 18 patients in protocol I (100%), and 31 of 33 
patients in protocol II (94%) were assessable for 
response. No objective response occurred in 
protocol I, whereas 15 of the 31 patients assessable 
for response in protocol II (48%) had objective 
response (4 complete responses, 11 partial 
responses) including one pathologically conﬁ  rmed 
complete response of a bone metastasis (fracture 
of a vertebra-body) (Table 2). Objective responses 
were diagnosed after a median time of 4.1 months 
(range 3.1 to 8.7 months). Responses occurred at 
all major tumor localizations (lung, pancreas, 
lymph-nodes, liver, bone, contra-lateral kidney). 
The metastases of patients with complete 
response were localized in the lung (n  =  3), liver 
(n  =  1), bone (n  =  1), and in lymph nodes (n  =  4). 
All these patients received prior tumor nephrec-
tomy. At ﬁ  rst relapse a chemoembolization of a 
metastasis was performed in one patient, another 
patient underwent surgical stabilization of a frac-
ture of a vertebra-body and radiation of a further 
bone metastasis prior to study inclusion.
An additional 14 patients of protocol II had 
stable disease. Three of these patients had a 
measurable reduction of the metastatic lesions’ size 
but did not meet the RECIST response criteria. 
Best response in study I was stable disease in 9 
patients (50%), another 9 patients suffered from 
continuous tumor progression. Only 2 of 31 
patients (5%) had progressive disease on regimen 
II. All patients of protocol I/II (94%/24%) died of 
tumor progression.
Progression-free survival of all patients enrolled 
on protocol I (n  =  18), and protocol II (n  =  33) is 
shown in Figure 1. After a median follow-up of 21 
months/22 months (study I/II) the median, 12- and 
24-month progression-free survivals were 4.7 
months, 13%, and 0% vs. 11.5 months, 49%, and 
24%. The overall survival is shown in Figure 2. 
The median, 12-, 24- and 36-month survivals were 
16.2 months, 61%, 21%, and 5% vs. 25.6 months, 
88%, 65%, and 48%, respectively.
The objective response rate for assessable 
patients of study II who did or did not receive 
previous systemic therapy (n = 6; n = 25) was 33% 
and 52%, respectively. Two responders received 
previously IFN-α. Progression-free survival rate 
was signiﬁ  cantly improved only for untreated 
patients of cohort I (p  =  0.03). The respective 
overall survival rates were not significantly 
different within both cohorts (p = 0.12).
Objective response to treatment was observed 
in all Motzer and Leibovich risk categories. 
Patients in low-, intermediate-, and high-risk 
categories (Motzer score) had major response of 
60%, 47% and 33%, respectively, patients in 
Table 2. Response to treatment: Study I and Study II.
                         Study I n = 18        Study II n = 31
Response category  No.  %  No.  %
        
Complete   0  0  4  13
Partial   0  0  11  35
Stable   9  50  14  45
Progression 9  50  2  7
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Figure 2. Overall survival (Study I: N = 18; Study II: N = 33). The median, 12, 24, and 36 months survivals are 16.2 months, 61%, 21% 
and 5% (study I) vs. 25.6 months, 88%, 65% and 48%, respectively (study II).
Figure 1. Progression-free survival (Study I: N  =  18; Study II: N  =  33). The median, 12 and 24 months progression-free survivals are
4.7 months, 13%, and 0% (study I) vs. 11.5 months, 49% and 24%, respectively (study II).
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Leibovich category –5 to –1, 0 to 2, 3 to 6, 7 to 9, 
had major response of 100%, 38%, 43%, and 40%. 
A category of patients at risk could not be identiﬁ  ed 
concerning progression-free or overall survival, 
probably due to the low number of patients in each 
risk group.
CRP response
CRP levels were available for follow-up in all 
patients assessable for response. Thirteen (72%) 
and 29 (93%) patients of cohort I/II had elevated 
CRP levels (CRP > 10 mg/dL) at study inclusion. 
The initial mean CRP levels of all assessable 
patients in cohort I/II (47.8 mg/dL/40.2 mg/dL) 
were not signiﬁ  cantly different, p = 0.63. Exclusively 
in cohort II mean CRP levels declined signiﬁ  cantly 
after 4–6 weeks on treatment (Figure 3): CRP levels 
decreased more than 30% in all patients with 
initially elevated CRP levels, in 24 of the 29 
patients (83%) for more than 60%. The association 
of CRP decline and tumor response is shown
Table 3. The CRP decline was in 22%/34% of the 
patients (protocol I/II) associated with an improve-
ment of the ECOG status. Three patients in study 
II with assessed microbial infections grade 3 did 
not develop corresponding CRP elevations.
Tolerability and safety
Both treatment regimens were aimed to facilitate 
long-term administration of the entire study medi-
cation by a scheduled early dose reduction in cases 
of toxicities > grade 1. Treatment-related toxicities 
are speciﬁ  ed in Table 4a/b. In 4 (I) and 5 (II) 
patients (22%/16%), respectively, the therapy with 
the respective COX-2 inhibitor was discontinued 
during further treatment. Dose reductions of one 
or more drugs were performed in 72%/64% of the 
patients (study I/II), mainly due to capecitabine 
associated toxicity (Table 5a/b). Dose reduction of 
pioglitazone was not required. 
Overall both therapy regimens were well toler-
ated. Due to renal insufﬁ  ciency (4/4 patients) and 
hypertension (1/1 patient) the COX-2 inhibitors 
were discontinued after 3 to 5 treatment cycles. 
Cardiac adverse events were not observed. Two 
patients of study II discontinued therapy because 
of drug-related toxicities after 2.5 months (depres-
sion grade 3) and 6 months (hand-foot-syndrome 
grade 3). Hematotoxicity was generally mild.
Mild fever reactions and depression were 
speciﬁ  cally related to the additional administration 
of low-dose IFN-α. Transiently 6 and 7 patients, 
respectively (study I/II), received mild diuretic 
therapy (weight gain, edema). Fatigue developing 
after the initiation of treatment with rofecoxib/
etoricoxib also was observed, albeit less frequently. 
All patients who experienced this side effect 
received the COX-2 inhibitor in the evening. Diar-
rhea, hand-foot-syndrome, nausea and vomiting 
were typically related to capecitabine. 
Discussion
The combination of the PPAR-γ agonist piogli-
tazone with a COX-2 inhibitor plus capecitabine 
resulted in negative response data and a moderate 
anti-inflammatory activity (study I). Study II 
assessed now, that the selected second transcription 
modulator, IFN-α besides pioglitazone, is comple-
mentary acting while tilting the systems biology 
of the tumor to a measurable response: Inﬂ  amma-
tion control in all patients with initially elevated 
CRP levels. Moreover, attenuation of the inﬂ  am-
matory activity was also established in single 
patients with clinically assessed infections. The 
successful disease modeling and the consecutively 
resulting tumor responses, as indicated by a steeply 
increasing response rate (0% vs. 48%, study I/II), 
Table 3. C-reactive protein and tumor response.
  Number of patients (%)
   with CRP response and
   with elevated  with CRP  objective  stable  progressive
   CRP levels  response  response  disease  disease
Study I  13 (72)  9 (69)  0  9 (100)  0
Study II  29 (93)  29 (100)  13 (45)  14 (48)  2 (7)
CRP = C-reactive protein; CRP response: >30% decline of serum CRP level within 4-6 weeks on 
study medication.
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Figure 3. C-reactive protein (CRP) response at study inclusion and after 4 to 6 weeks on treatment. In study I mean CRP levels decline 
from 47.8 mg/dl (standard deviation 40.4 mg/dl) to 37.5 mg/dl (standard deviation 37.2 mg/dl), p = 0.33, in study II from 40.1 (standard de-
viation 38.0) to 4.9 (standard deviation 3.9 mg/dl), p = 0.0005. The mean initial CRP levels of cohort I and II were not signiﬁ  cantly different, 
p = 0.63.
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Table 4b. Treatment-related toxicity Study II (n = 31).
  Toxicity Grade 1/2  Toxicity Grade 3  Toxicity Grade 4
  No.  %  No. %  No. %
Diarrhea  6  (19)  - -  - -
Hand-foot-syndrome 8  (26) 3  (10) -  -
Nausea/Vomiting  1 (3)  - -  - -
Edema  6  (19)  - -  - -
Creatinine  elevation  8  (26)  - -  - -
Hypertension 1  (3)    -  -  -
Fever  2 (6)  - -  - -
Fatigue  3  (10)  - -  - -
Depression -  -  1  (3)  -  -
Leukocyte  counts  3  (10)  - -  - -
Platelet  count  2 (6)  - -  - -
Hemoglobin  level  3  (10)  - -  - -
Urinary tract infections  -  -  3  (10)  -  -
Table 4a. Treatment-related toxicity Study I (n = 18).
  Toxicity Grade 1/2  Toxicity Grade 3  Toxicity Grade 4
  No. %  No. %  No. %
Diarrhea 4  (22)  -  -  -  -
Hand-foot-syndrome 2  (11)  1  (6)  -  -
Nausea/Vomiting  2 (11)  2 (11)  -  -
Edema 4  (22)  1  (6)  -  -
Hypertension 1  (6)  -  -  -  -
Creatinine elevation  7  (39)  -  -  -  -
Leukocyte counts  2  (11)  1  (6)  -  -
Anemia 5  (28)  -  -  -  -
are revealing a strong concerted biomodulatory 
activity of these at the respective doses in mono-
therapy rather inefﬁ  cacious drugs [Creagan et al. 
1991]. 
Inﬂ  ammation control seems to preceed tumor 
response and to occur independently of response 
behavior, either in cases with complete (patho-
logic) response or in those with rapidly progressive 
disease. Therefore, the CRP level represents no 
tumor marker, but an important biomarker for 
monitoring response to treatment of a cancer-
related disease trait (tumor-related inﬂ  ammation): 
A CRP decrease indicates the control of an either 
tumor-related or probably tumor-unrelated inﬂ  am-
matory process. The clinical equivalent is a corre-
sponding improved ECOG status. 
Approaches for a tailored modeling of tumor-
associated disease traits, such as immunologic 
disorders and inﬂ  ammation, owing to ubiquitous 
accessible transcription pathways in tumor and 
neighboring stroma cells (IL-2 and IFN-α receptor, 
retinoid X and glucocorticoid receptor) have been 
intensively studied in RCC. Previous phase III 
trials have tested the efﬁ  cacy of various combina-
tions of transcription modulators (IFN-α, IL-2, 
13-cis-retinoic acid, glucocorticoids) plus/minus 
chemotherapy [Creagan et al. 1991; Atzpodien 
et al. 2004; no authors listed, 1999; Pyrhonen
et al. 1999; Aass et al. 2005]. These studies are 
consistently demonstrating that just the concerted 
action of transcription modulators (mostly at high 
or maximal tolerable doses) is able to capture on 
a relatively small scale the strength of a negative 
regulation of growth promoting activities: The 
more transcription modulators are being included 
in a treatment arm (1 vs. >1), the better the respec-
tive response rates in comparison to the control 
arm, irrespective of the combinations or whether 
chemotherapy was added. Unfortunately, in all the 
same order the therapeutic index is steeply 
decreasing as indicated by an increasing incidence 
of grade 3 and 4 toxicities [Atzpodien et al. 2004]. 
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Best response rates for high-dose IFN-α in these 
phase III trials are reported to range between 3–13% 
(PFS 2.7–5.0 months), for respective combination 
therapies between 8–26% (PFS 1.9–7.0 months). 
Most importantly, these phase III trials did not 
establish a similar stringent surrogate marker indi-
cating a sufﬁ  cient disease modeling either on an 
immunologic or inﬂ  ammatory level. In the contrary, 
some trials are assessing inﬂ  ammation as impeding 
factor for a successful therapy [Kedar et al. 
2004]. 
 Approaches targeting tumor-associated angio-
genesis have recently been established in ﬁ  rst-line 
therapy of metastatic RCC: Including multitar-
geted kinase inhibitors such as sorafenib or 
SU11248 in ﬁ  rst and second-line therapy of RCC 
objective response rates are observed in up to 40% 
of the cases, and PFS is ranging between 6 to 8.3 
months [Motzer et al. 2006; Ratain et al. 2006]. 
The speciﬁ  c inhibition of VEGF by the mono-
clonal antibody bevacizumab induces response 
rates of 13% in patients with metastatic CCRC 
(PFS 8.5 months) [Bukowski RM et al. 2006]. 
Data of the current study are showing now, that 
anti-infammatory therapy in metastatic CCRC 
may be an additional important therapy approach 
besides the established angiostatic and immuno-
logic therapy strategies.
The emerging pre-clinical data on the co-regu-
latory activities of transcription modulators under-
line our clinical observations as well as in vitro 
data on the reversal of IFN-α resistance following 
the addition of curcumin, a drug with PPARγ 
agonistic activity [Smith and O’Malley, 2004; 
Ogawa et al. 2005; Lee et al. 2005]. The extent of 
the combined activity of pioglitazone and IFN-α 
could be overestimated by possible chemosensi-
tizing effects or other additive drug interactions 
with COX-2 inhibitors [Angelo et al. 2002; Rini 
et al. 2006; Kohno et al. 2005; Atzpodien et al. 
2006]. Ongoing studies have to specify those 
effects. The multitude of activities ascribed for the 
different drugs used suggest that a precise mecha-
nism for the schedules’ activity may be difﬁ  cult to 
pin down [de Visser and Coussens, 2005]. However, 
the current study might indicate that (1) the 
capacity for a negative receptor-triggered regula-
tion of pro-inﬂ  ammatory responses is still preserved 
in the CCRC tissue (therapeutic plasticity) [Pfeffer 
et al. 1996; Tuna et al. 2004; Inoue et al. 2001].
(2) A possible starting-point for an effective thera-
peutic intervention has been recognized in the 
limitation of the activity of pro-inflammatory 
cytokines. 
Targeted modeling of metastatic disease by 
focusing on the control of evolving pathophysio-
logically relevant disease traits during metastatic 
stage could be unifying therapeutic approaches for 
different tumor types. Combined transcription 
modulation is suggested to minimize regimen-
related toxicity and to improve tumor response by 
disease modeling. This new therapeutic model 
Table 5a. Dose modiﬁ  cations in Study I (n = 18).
Dose modiﬁ  cation
  No. of patients
 Capecitabine  Etoricoxib/Rofecoxib
1g absolute twice daily  3  - / -
12.5 mg daily  -  - / 7
Interruption of therapy (< 2 weeks)  3  2 / 7
Table 5b. Dose modiﬁ  cations in Study II (n = 31).
Dose modiﬁ  cation
 No.  of  patients
 Capecitabine  interferon-α        Etoricoxib/Rofecoxib
1g absolute twice daily  12  -  -/-
3 MU three times a week  -  11  -/-
12.5 mg daily  -  -  -/9
interruption of therapy (< 2 weeks)  8  3  2/9
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might be easily integrated into more comprehen-
sive treatment approaches.
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